**Participant Flow** (this data has not been published previously, but will be published soon elsewhere)

```
                  ┌─────────────────┐        ┌──────────────────────┐
                  │  Participants   │        │ Enrolment            │
                  │   (n=334)       │        │                      │
                  └─────────────────┘        └──────────────────────┘
                    ╱            ╲
┌─────────────────────────┐  ┌──────────────────────┐  ┌──────────────────────┐
│ Intervention group      │  │ Control group (n=206)│  │ Intervention allocation│
│ (n=128)                 │  │                      │  │                      │
└─────────────────────────┘  └──────────────────────┘  └──────────────────────┘
            │                          │
┌─────────────────────────┐  ┌──────────────────────┐
│       Drop Out          │  │     Drop Out         │
│ Died (n=7)              │  │ Died (n=13)          │
│ Other reasons (n=3)     │  │ Other reasons (n=6)  │
└─────────────────────────┘  └──────────────────────┘
            │                          │
┌─────────────────────────┐  ┌──────────────────────┐  ┌──────────────────────┐
│ Complete follow up      │  │ Complete follow up   │  │ Follow-up            │
│ (n=118)                 │  │ (n=189)              │  │                      │
└─────────────────────────┘  └──────────────────────┘  └──────────────────────┘
```

Figure 1: Participant flow; other reasons were mainly change of involved PCP

## Baseline Characteristics (this data has been published previously[1])

| Patients | |
|---|---|
| Sex (n, %) | 334 |
| Male | 152 (46%) |
| Female | 182 (54%) |
| Age (mean, SD) | 76.18 (8.45) |
| Weight (mean, SD) | 76.80 (16.06) |
| Blood pressure systolic (mean, SD) | 137.65 (18.7) |
| diastolic (mean, SD) | 75.44 (12.08) |
| Number of drugs (mean, SD) | 8.46 (2.94) |
| Subjective pain assessment, *Visual Analogue Scale* VAS (mean, SD) | 4.18 (2.50)* |
| Quality of life, QoL (mean, SD) | 0.77 (1.55)** |
| Health status | 65.83 (17.86)*** |
| Living situation Living at home alone (n, %) | 119 (36%) |
| Living at home with family (n, %) | 173 (52%) |
| Living in nursing home (n, %) | 38 (11%) |
| **PCP`s** | |
| Sex PCP`s (n, %) | 46 |
| Male | 30 (65%) |
| Female | 16 (35%) |
| Age (mean, SD) | 49.42 (9.32) |
| Years of working experience (mean, SD) | 13.62 (9.73) |
| Working in single practice (n, %) | 10 (22%) |
| Practice connected to network (n, %) | 21 (46%) |

**Table 1:** Characteristics of patients and GPs included

* Value on a scale from 1 to 10 (10 centimeter long)

** Value on a scale from -2 to +2

*** Value on a scale from 0 to 100

## Outcome Measures (this data has not been published previously, but will be published soon elsewhere)

| Group Differences (p-value) | Pre-Intervention | Post-Intervention (immediately after) | 6 months post-Intervention | 12 months post-Intervention |
|---|---|---|---|---|
| | T0 | T1 | T2 | T3 |
| Number of drugs<br>Intervention group<br>Control group<br>p | 8.02 (SD 2.51)<br>8.05 (SD 2.53)<br>0.916 | 7.20 (SD 2.27)<br>8.05 (SD 2.53)<br>0.002 | 7.54 (2.62)<br>8.01 (SD 2.55)<br>0.117 | 7.64 (SD 2.59)<br>7.68 (SD 2.47)<br>0.906 |
| Differences QoL, EQ-5D, 0-100 (pt) | 2.075 (p=0.306) | | 2.025 (p=0.327) | 1.790 (p=0.383) |
| Differences QoL, (-2 to 2) | 0.085 (p=0.939) | | 0.082 (p=0.479) | 0.016 (p=0.491) |
| Differences in functional EQ-5D | 0.024 (p=0.541) | | 0.057 (p=0.183) | 0.036 (p=0.384) |

**Table 2:** Differences between groups at the four time points (with significance level), primary outcome difference in number of drugs after 12 months (yellow background), all other data concerns secondary outcomes. Abbreviations: QoL = Quality of life

|  | First consultation T0 | 6 months T1 | 12 months T2 | P (T0 - T2) | P (T0 - T3) |
|---|---|---|---|---|---|
| **Intervention group** |  |  |  |  |  |
| QoL, EQ-5D, 0-100 (pt) | 67.1 | 65.9 | 67.2 | 0.615 | 0.955 |
| QoL (-2 bis 2) | 0.59 | 0.56 | 0.58 | 0.794 | 0.948 |
| Func EQ-5D | 1.49 | 1.48 | 1.46 | 0.814 | 0.462 |
| **Control group** |  |  |  |  |  |
| QoL, EQ-5D, 0-100 (pt) | 65.0 | 67.9 | 69.0 | 0.093 | 0.025 |
| QoL (-2 bis 2) | 0.59 | 0.64 | 0.66 | 0.685 | 0.539 |
| Func EQ-5D | 1.47 | 1.43 | 1.43 | 0.222 | 0.179 |

**Table 3:**

Intervention and control group: QoL/secondary outcomes during 12 months (at 3 time points); significance of the differences between measurements at different time points. Abbreviations: QoL = Quality of life

**Adverse Events** (this data has not been published previously, but will be published soon elsewhere)

There were no adverse events associated with this trail. (if associated means that they were directly caused by the trial intervention) otherwise see below.

| | Intervention group | Control group | Group comparison significance p <0.05 T0 – T2 |
|---|---|---|---|
| **Reported events** | 58 (45.31%) | 61 (29.61%) | 0.3181 |
| **Hospitalisations** | 43 (33.59%) | 54 (26.21%) | 0.162 |
| **Deaths** | 7 (5.47%) | 13 (6.31%) | 0.9544 |

**Table 4:** Absolut numbers of reported events (by PCPs), hospitalisations and deaths during the whole trial period in both groups.

1.    Neuner-Jehle S, Zechmann S, Grundmann Maissen D, Rosemann T, Senn O. Patient-provider concordance in the perception of illness and disease: a cross-sectional study among multimorbid patients and their general practitioners in Switzerland. *Patient preference and adherence.* 2017;11:1451-1458.